2P4.F BIOPORTO A/S B DK 1

Healthcare Biotechnology Frankfurt Exchange
0.1160 EUR
Close of Nov 11, 2026
0.0980 0.1685
Market cap
EUR 57.4M
P/E
-
P/B
5.34x
ROE
174.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is 2P4.F undervalued?

Graham number

The Graham number of BIOPORTO A/S B DK 1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOPORTO A/S B DK 1 fundamental analysis

No fundamental analysis for BIOPORTO A/S B DK 1 yet.

BIOPORTO A/S B DK 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOPORTO A/S B DK 1

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma,…

Full company profile